| Paris | |
| 225 | |
| Vaccine development and antibody discovery with revenues from a vaccine for Japanese encephalitis and licensed technology platforms | |
| Valnevas Japanese encephalitis vaccine is licensed in more than thirty-five countries. It is marketed under the trade names IXIARO® in North America, Europe, Hong Kong, Singapore and Israel and under the trade name JESPECT® in Australia and New Zealand where it is distributed by bioCSL. Valneva's partner Biological E. Ltd. commercializes the Japanese encephalitis vaccine under the trademark JEEV® in India, Pakistan, Nepal and Bhutan. This product is based on Valnevas technology and manufactured at Biological E.s facility in Hyderabad, India. The Pseudomonas aeruginosa program is in Phase II/III development and is part of the strategic alliance between GSK and Valneva. Valneva aims at developing a vaccine for the prevention of primary Clostridium difficile infection using an age-and risk-based vaccination approach, in persons of advanced age with upcoming hospitalizations or underlying chronic conditions, and eventually for community-wide prophylaxis on an age-based vaccination strategy. Valneva has developed a multivalent, protein subunit based vaccine candidate against Lyme borreliosis.This candidate has completed pre-clinical development and is currently in the pre-IND-process including regulatory advice and consultation processes (both of which have been completed). Valneva expects to initiate a phase I clinical study in H2 2016. |
|
| BACHELOT-FONTAINE Laetitia | |
| www.valneva.com | |
| VLA:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 8 fois.